The Neuroethics of Biomarkers : What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder (Oxford Series in Neuroscience, Law, and Philosophy)

個数:

The Neuroethics of Biomarkers : What the Development of Bioprediction Means for Moral Responsibility, Justice, and the Nature of Mental Disorder (Oxford Series in Neuroscience, Law, and Philosophy)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 224 p.
  • 言語 ENG
  • 商品コード 9780190236267
  • DDC分類 174.29689

Full Description

Neuroscientists are mining nucleic acids, blood, saliva, and brain images in hopes of uncovering biomarkers that could help estimate risk of brain disorders like psychosis and dementia; though the science of bioprediction is young, its prospects are unearthing controversy about how bioprediction should enter hospitals, courtrooms, or state houses. While medicine, law, and policy have established protocols for how presence of disorders should change what we owe each other or who we blame, they have no stock answers for the probabilities that bioprediction offers. The Neuroethics of Biomarkers observes, however, that for many disorders, what we really care about is not their presence per se, but certain risks that they carry. The current reliance of moral and legal structures on a categorical concept of disorder (sick verses well), therefore, obscures difficult questions about what types and magnitudes of probabilities matter. Baum argues that progress in the neuroethics of biomarkers requires the rejection of the binary concept of disorder in favor of a probabilistic one based on biological variation with risk of harm, which Baum names a "Probability Dysfunction. " This risk-reorientation clarifies practical ethical issues surrounding the definition of mental disorder in the DSM-5 and the nosology of conditions defined by risk of psychosis and dementia. Baum also challenges the principle that the acceptability of bioprediction should depend primarily on whether it is medically useful by arguing that biomarkers can also be morally useful through enabling moral agency, better assessment of legal responsibility, and fairer distributive justice. The Neuroethics of Biomarkers should be of interest to those within neuroethics, medical ethics, and the philosophy of psychiatry.

Contents

Introduction
Chapter 1: The Biomedical Promise Of Biomarkers
Chapter 2: Bioprediction Of Brain Disorder: Definitions And Scope
PART I: REORIENTATION OF THE CONCEPT OF DISORDER
Chapter 3:"There Is More Light Here." Re-Illuminating The Categories Of Mental
Chapter 4: The Probability Dysfunction
Chapter 5: The Practical Ethics Of Predictive Markers In Diagnosis: Can Risk Banding Address The Ethical Controversy Surrounding "Psychosis Risk Syndrome" And "Preclinical Alzheimer's Disease"?
PART II: BIOPREDICTION AND MORAL RESPONSIBILITY
Chapter 6: Enhanced Responsibility: Foreseeability And New Obligations To Others
Chapter 7: Reduced Responsibility: Distinguishing Conditions In Which Biomarkers Properly Reduce Legal Responsibility
PART III: BIOPREDICTION AND SOCIETY
Chapter 8: Bioprediction And Priority
Conclusion
Appendix I
Appendix II
Appendix III
References
Index

最近チェックした商品